VVUS Ceo on Kadmon..... "We recently initiated a specialty sales force co-promotion pilot program with Kadmon Corporation intended to introduce Qsymia to new potential prescribers specifically liver disease specialists. This pilot program will be evaluated at year end 2015".
Are you nuts?
We won't see you boy once this train to speed.
Management is wating for the USA senate obesity legislation.
Stop your bulshit.
I bought VVUS at $2.70 and wont sell it before it goes to $30!
1. Obesity on the congress agenda
2. $290 million on the Bank account
3. New institutions just bought and increase their positions.
4. ANDP re-launches Stendra
5. Qsymia on Kadmon web page (interesting)
6. Change in management…
7. Market value below $200 million.
VVUS will be fine !
Introduced in Senate (06/04/2015)
Treat and Reduce Obesity Act of 2015
Amends title XVIII (Medicare) of the Social Security Act to authorize the Department of Health and Human Services (HHS), in addition to qualified primary care physicians and other primary care practitioners, to cover intensive behavioral therapy for obesity furnished by: (1) a physician who is not a qualified primary care physician; (2) an evidence-based, community-based HHS-approved lifestyle counseling program; or (3) any other appropriate health care provider (including a physician assistant, nurse practitioner, clinical nurse specialist, a clinical psychologist, and a registered dietitian or nutrition professional).
Allows coverage of intensive behavioral therapy for obesity furnished by another appropriate health care provider or program only if it is furnished: (1) upon referral from, and in coordination with, a physician or primary care practitioner in a primary care or other HHS-specified setting; and (2) in an office setting, a hospital outpatient department, a community-based site that complies with the federal regulations concerning the privacy of individually identifiable health information, or another HHS-specified setting.
Authorizes HHS to cover under Medicare part D (Voluntary Prescription Drug Benefit Program) medication for treatment of obesity or for weight loss management for an overweight individual with one or more related comorbidities.
Why the SEC ignore the short players from reporting their position?
I think the SEC should a forces the shorts to report their position
to avoid corruption and destroying companies.
Is there any list of VVUS short players the same as the long players?
If we know who are the short players we might understand their interest.
The current situation is very strange.
I wonder if the bond holders are the short players.